Parkinson’s Disease Overview
Parkinsons disease (PD), is a chronic, progressive neurodegenerative disorder. It is caused primarily by the degeneration of dopaminergic neurons in the substantia nigra. This leads to dopamine deficiency in the striatum, disrupting basal ganglia circuits responsible for smooth and coordinated movement. The classical motor symptoms include resting tremor, bradykinesia, rigidity, and postural instability (Hariz & Blomstedt, 2022).
Global prevalence is rising, partly due to population aging. Estimates exceed 5–10 million individuals worldwide (Foote et al., 2025). Symptoms typically begin mildly but progress over time, leading to increasing dependence and disability.
Although no cure exists, current treatments including medication, rehabilitation, and neuromodulation can substantially improve symptom control in those affected by Parkinsons Disease. These treatments help maintain functional independence and enhance quality of life for individuals living with PD.
Why DBS for Parkinsons Disease?
Deep brain stimulation (DBS) is a key treatment option for people with Parkinson’s disease (PD). It is for those whose symptoms are no longer adequately controlled with medication alone. As PD progresses, many patients develop motor fluctuations.
DBS is especially valuable because it is adjustable, reversible, and long-term. Unlike lesion-based procedures, DBS does not permanently destroy brain tissue; instead, clinicians can fine-tune stimulation parameters to match the patient’s symptom severity and progression over time. Both the subthalamic nucleus (STN) and the globus pallidus internus (GPi) are well-established DBS targets, and stimulation of either region can significantly improve bradykinesia, rigidity, tremor, and motor complications (Deuschl et al., 2006; Weaver et al., 2012). Patients who previously experienced unpredictable medication response often report smoother control and more stable daily functioning after DBS.
Another major advantage of DBS is its impact on medication burden. Many individuals undergoing STN DBS are able to reduce their dopaminergic medication by 30–50%, which helps decrease dyskinesias and medication-related side effects (Perestelo-Pérez et al., 2014). GPi DBS, while usually associated with less medication reduction, can provide strong suppression of dyskinesias even without lowering drug dosage (Wagle Shukla et al., 2025).
Beyond motor symptoms, DBS can improve sleep quality and reduce pain. It enhances daily independence, leading to better overall quality of life.
DBS Procedure & Targets
Deep brain stimulation (DBS) works by delivering controlled electrical pulses to specific brain regions involved in Parkinson’s disease motor circuitry. The procedure is typically performed by a multidisciplinary team. This includes a movement-disorder neurologist, a functional neurosurgeon, and DBS programming specialists.
The two primary targets for Parkinson’s disease are the subthalamic nucleus (STN) and the globus pallidus internus (GPi). STN DBS is widely used because it can improve motor symptoms and often allows a reduction in dopaminergic medication. GPi DBS is equally effective for improving motor function but is especially beneficial for controlling dyskinesias and may have fewer mood or cognitive side effects in certain patients (Perestelo-Pérez et al., 2014). A third target, the ventral intermediate nucleus (VIM) of the thalamus, is generally reserved for tremor-dominant disease, particularly in patients whose primary disabling symptom is medication-resistant tremor (Deuschl et al., 2006).
The surgical process involves implanting thin electrodes through a small skull opening using stereotactic navigation. High-resolution MRI and CT imaging guide the trajectory, and some centers use microelectrode recordings to refine accuracy. After placement, the electrodes are connected to an implantable pulse generator (IPG) positioned under the skin of the chest (Weaver et al., 2012).
Programming begins a few weeks after surgery. Clinicians adjust frequency, pulse width, and amplitude to optimize benefit while minimizing side effects. Modern systems incorporate directional leads, which allow current steering toward therapeutic pathways and away from regions causing speech or balance problems. These advances have expanded the therapeutic window and improved long-term tolerability (Foote et al., 2025).
Overall, precise targeting, patient selection, and expert programming are key to achieving durable and meaningful clinical outcomes with DBS.
Clinical Outcomes & Long-Term Efficacy
Deep brain stimulation (DBS) provides some of the most consistent and durable clinical benefits available for patients with Parkinson’s disease. Across multiple randomized controlled trials and long-term cohort studies, stimulation of either the subthalamic nucleus (STN) or globus pallidus internus (GPi) leads to marked improvement in cardinal motor symptoms. This includes tremor, rigidity, and bradykinesia.
One of the most clinically meaningful advantages of DBS is its effect on motor fluctuations. Patients commonly experience smoother transitions throughout the day, fewer sudden “off” episodes, and significant relief from levodopa-induced dyskinesias. GPi DBS is particularly effective for dyskinesia suppression, while STN DBS often allows a 30–50% reduction in medication dosage, contributing to reduced side effects and improved overall tolerability (Perestelo-Pérez et al., 2014).
Long-term studies consistently show that DBS maintains its therapeutic impact for many years. A recent five-year evaluation demonstrated sustained improvement in motor symptoms and functional performance.
Importantly, DBS has been shown to positively influence quality of life. Improvements in mobility, independence, speech-related function, and participation in daily activities are consistently reported across both STN and GPi cohorts. Patients benefit not only from reduced symptom burden but also from greater reliability in day-to-day function, fewer medication side effects, and improved sleep, mood, and energy levels documented in modern neuromodulation research (Foote et al., 2025).
Overall, the evidence demonstrates that DBS is a highly effective and durable therapy for appropriately selected patients. It provides substantial short-term improvements in motor control and long-term stability of benefit, outperforming medication adjustments alone and offering sustained gains in mobility, independence, and quality of life.
Side Effects & Safety Profile
Deep brain stimulation (DBS) is considered a safe and well-established therapy for Parkinson’s disease when performed in experienced centers. Surgical risks include infection, lead misplacement, wound complications, and rarely intracranial hemorrhage. Large prospective trials such as those by Deuschl et al. and Weaver et al. confirmed that serious surgical complications remain uncommon and comparable to other stereotactic neurosurgical interventions (Deuschl et al., 2006; Weaver et al., 2012).
Most side effects are stimulation-related rather than surgical. Because DBS delivers current to deep brain structures, unintended spread of stimulation can cause speech difficulty, balance problems, muscle tightness, tingling sensations, or transient mood changes. These effects are typically reversible and can be corrected by adjusting contact selection, amplitude, pulse width, or frequency. GPi stimulation is often preferred when reducing neuropsychiatric side effects is a priority, as it may have a more favorable cognitive and mood profile compared with STN DBS in certain patients (Perestelo-Pérez et al., 2014).
Advances in neuromodulation technology have further improved safety. Directional leads allow clinicians to steer current away from structures responsible for side effects, while modern programming algorithms increase the therapeutic window and reduce unwanted stimulation. Long-term follow-up evidence shows stable hardware reliability and low rates of lead fracture or device malfunction over many years (Starr et al., 2025).
Overall, DBS has a well-documented safety record. Most adverse effects are mild, adjustable, and manageable with expert programming. With appropriate patient selection and multidisciplinary care, DBS remains one of the safest advanced therapies for Parkinson’s disease.
DBS vs Other Treatment Options
The management of Parkinson’s disease (PD) traditionally begins with dopaminergic medications, particularly levodopa. While these remain the most effective therapy for improving motor symptoms, many patients develop motor fluctuations and unpredictable “off” periods as the disease progresses.
Several non-surgical options exist, including continuous levodopa–carbidopa intestinal gel (LCIG) and apomorphine infusion. These infusion therapies smooth out motor fluctuations by providing more continuous dopaminergic stimulation. Although effective for reducing “off” time, they require ongoing pump maintenance, can cause device-site complications, and generally have limited impact on disabling tremor or severe dyskinesias.
Ablative procedures such as MRI-guided focused ultrasound (MRgFUS) and radiofrequency thalamotomy or pallidotomy offer alternatives for select patients who are not surgical candidates for DBS. These lesioning techniques can be effective for tremor control but are irreversible, typically unilateral, and may carry higher risk of speech or gait problems when applied bilaterally. In contrast, DBS is reversible, programmable, and can be performed bilaterally with a more favorable long-term safety profile (Deuschl et al., 2006).
DBS stands out due to its ability to address multiple symptom domains simultaneously. This includes tremor, rigidity, bradykinesia, motor fluctuations, and dyskinesias.
Long-term data further differentiate DBS from other options. Five-year follow-up research demonstrates that motor improvements, reduction in dyskinesias, and daily functional gains remain durable over time, despite natural disease progression (Starr et al., 2025). This contrasts with medication-based strategies, which typically require escalating doses and provide diminishing benefit over the same period.
Overall, while medications and infusion therapies remain valuable components of PD treatment, DBS offers broader symptom control, greater long-term stability, and improved quality of life. For appropriately selected individuals, DBS is the most effective and adaptable advanced therapy available for Parkinson’s disease.
Advances in Parkinson’s Neuromodulation
Recent years have brought major advances in neuromodulation for Parkinson’s disease. These improvements enhance both the precision and long-term effectiveness of deep brain stimulation (DBS).
Another important development is adaptive DBS (aDBS). Traditional DBS delivers continuous stimulation, but adaptive systems use real-time neural signals such as beta oscillations recorded from the implanted lead to adjust stimulation automatically. Early clinical evidence shows that aDBS may reduce energy consumption, prolong battery life, and provide more physiologic control of symptoms with fewer side effects (Sandoval-Pistorius et al., 2023).
Advances in sensing-enabled implantable pulse generators have also transformed clinical practice. These systems record brain activity chronically, helping clinicians identify biomarkers associated with tremor, bradykinesia, or dyskinesia, and enabling more informed programming decisions over time (Wagle Shukla et al., 2025).
Improvements in imaging and tractography-guided targeting now allow surgeons to visualize patient-specific motor pathways with far greater accuracy than traditional methods. This enhances electrode placement within the subthalamic nucleus (STN) or globus pallidus internus (GPi).
Hardware innovations including rechargeable IPGs, smaller device footprints, and MRI-compatible systems have further enhanced patient comfort and long-term usability. Research trends also show growing interest in combining DBS with gene therapy, closed-loop stimulation, and advanced computational modeling to better understand and modulate dysfunctional networks (Zhao et al., 2024).
Overall, these advances are reshaping the field of neuromodulation. They make DBS safer, more targeted, and more adaptable to the evolving needs of individuals living with Parkinson’s disease.
References
Deuschl, G., Schade-Brittinger, C., Krack, P., et al. (2006). Deep brain stimulation for Parkinson’s disease. New England Journal of Medicine, 355, 896–908.
Foote, A., et al. (2025). A comprehensive review of deep brain stimulation for Parkinson’s disease. Journal of Parkinsonism and Movement Disorders, 4(1), 1–15.
Hariz, M., & Blomstedt, P. (2022). Deep brain stimulation for Parkinson’s disease: A systematic review. Journal of Internal Medicine, 292, 764–786.
Perestelo-Pérez, L., Rivero-Santana, A., Pérez-Ramos, J., Serrano-Pérez, P., Panetta, J., & Hilarión, P. (2014). Deep brain stimulation in Parkinson’s disease: Meta-analysis of randomized controlled trials. Journal of Neurology, 261, 2051–2060.
Sandoval-Pistorius, S. S., et al. (2023). Advances in deep brain stimulation: From mechanisms to current uses. The Journal of Neuroscience, 43(45), 7575–7586.
Starr, P. A., et al. (2025). Five-year outcomes from deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson disease. JAMA Neurology, 82(2), 1–13.
Wagle Shukla, A., et al. (2025). Patient, target, device, and program selection for deep brain stimulation in Parkinson’s disease. NPJ Parkinson’s Disease, 11(1), 1–12.
Weaver, F. M., Follett, K., Stern, M., et al. (2012). Randomized trial of deep brain stimulation for Parkinson disease. Neurology, 79, 55–65.
Zhao, W., et al. (2024). Deep brain stimulation research trends in Parkinson’s disease: A bibliometric analysis. Frontiers in Aging Neuroscience, 16, 1413074.
In summary, the ongoing research and clinical advances underscore the importance of understanding and managing Parkinsons Disease effectively.